Previous 10 | Next 10 |
Palm Beach, FL –– February 24, 2022 – FinancialNewsMedia.com News Commentary – The prevalence of mental health disorders has risen exponentially but the development of novel medications has not kept pace, precipitating a crisis in psychiatric me...
Shares of the clinical-stage cell therapy company Atara Biotherapeutics (NASDAQ: ATRA) are under heavy pressure today following a fatality in an ongoing, early-stage dose escalation trial. In response to this clinical setback, the biotech's shares were down by a hefty 12% as of 9:49...
Gainers: Creative Medical Technology (NASDAQ:CELZ) +33%. HOOKIPA Pharma (NASDAQ:HOOK) +18%. Zynex ZYXI +17%. AMN Healthcare Services (NYSE:AMN) +15%. ShockWave Medical (NASDAQ:SWAV) +10%. Losers: Baudax Bio (NASDAQ:BXRX) -11%. Nuvectis Pharma (NASDAQ:NVCT)...
Atara (NASDAQ:ATRA) is trading ~12% lower in the pre-market on Friday after the company reported a fatal serious adverse event (SAE) in a patient who received its experimental chimeric antigen receptor (CAR) T-cell therapy, ATA2271, in a Phase 1 trial for mesothelioma. After notifyi...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, developing transformative therapies for patients with cancer and autoimmune diseases, today reported Memorial Sloan Kettering Cancer Center’s (MSK) notification to the U.S. Food and Drug Administrat...
Live Conference Call and Webcast at 4:30 p.m. EST Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoi...
Seth Klarman’s 13F portfolio value decreased from $10.88B to $10.13B this quarter. Baupost Group added Fiserv while dropping eBay and International Flavors & Fragrances. The portfolio continues to be heavily concentrated with the top three positions accounting for ~35% ...
Fujifilm to Acquire Atara’s Cell Therapy Manufacturing Facility for Total Upfront Financial Consideration of USD 100 Million Parties to Enter Long-Term Supply Agreement for Clinical and Commercial Product Manufacturing Transaction Expected to Result in Reduced O...
Aberrant Immune Response to EBV Protein Triggers the Immune System to Attack and Destroy Myelin, Leading to Onset and Progression of Multiple Sclerosis (MS) Findings Reinforce Potential for ATA188 to Treat the Cause of MS by Specifically Targeting EBV-Infected B cells and Plas...
Significant Progress Achieved Against Strategic Priorities for ATA188, Tab-cel ® and CAR T Programs in 2021 ATA188 Granted FDA Fast Track Designation for Both Non-Active PPMS and Non-Active SPMS in Recognition of Potential to Address Significant Unmet Medical Need ...
News, Short Squeeze, Breakout and More Instantly...
Atara Biotherapeutics Inc. Company Name:
ATRA Stock Symbol:
NASDAQ Market:
Atara Biotherapeutics Inc. Website:
Prescription Drug User Fee Act (PDUFA) Target Action Date of January 15, 2025 If Approved, Tab-cel Would Be First Approved Therapy in U.S. for EBV+ PTLD BLA Acceptance Triggers $20 Million Milestone Payment from Pierre Fabre Laboratories, with Additional $60 Million Milestone if A...
Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Pascal Touchon, President and Chief E...
2024-06-27 22:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...